Writer, Partner at Lowenthal Capital Partners

With emphasis on biotechnology, Trevor focuses his portfolio on undervalued micro and small-cap companies. As a contributor to TalkMarkets, he hopes to elucidate undervalued companies that are exploring revolutionary treatment modalities for a wide spectrum of rare and devastating medical ... more

ALL CONTRIBUTIONS

E Talking With NuLife's CEO About Transplants And Technology
NuLife is a very early stage, precommercialization company exploring alternatives to transplants, initially for kidney patients.
Read
E Interview With First Choice Healthcare Solutions
I had the opportunity to interview Chris Romandetti. the CEO of First Choice Healthcare Solutions. FCHS is a network of non-physician owned medical centers. It is listed on the OTC market and trades at $1.53/share; the stock is worth a closer look.
Read
E BioSig: An Emerging Medical Device Developer Making Strides In Catheter-Based Electrophysiology
In this exclusive interview, CEO Gregory Cash provides an overview of BioSig's business developments and future prospects.
Read
E Pfizer: A Hot Stock With New Blockbuster Breast Cancer Drug
Palbociclib received accelerated FDA approval earlier this quarter. With annual sales estimates in the billions, I believe Pfizer could be a hot stock to own in 2015.
Read
E Arch Therapeutics Is A Life Sciences Company To Put On Your Radar: CEO Terrance Norch
In this exclusive interview, Dr. Terrance Norch highlights Arch Therapeutics' compelling value proposition.
Read
E Is China Biologic Products Poised To Tumble?
The company's valuation has increased exponentially in a very short period of time. With a major earnings event approaching, is it time to take profits or ride the post-earnings volatility?
Read

Comments

Latest Comments
Put Options: The Smart Way To Buy
4 years ago

Hi Chad, thanks for the article! Really informative. Just curious, do you recommend selling puts on any particular stocks? Also, what do you think about conservative put investing? By that I mean selling puts way in the money for a very small premium, so essentially there is little probability that you will pick up the shares?

In this article: PCLN
Stocks That Have Investors (Including Me) Excited
4 years ago

Nevertheless, it was a gamble. I don't like AMZN as a long-term investment because I don't think the company's value proposition is convincing.

In this article: FB, AMZN, TMO, CFR, UNH
Stocks That Have Investors (Including Me) Excited
4 years ago

I agree with you, to some extent. I sort of took a gamble on an AMZN $310 Jan 17 Call a month or so ago, and it really paid off. Certainly gains to be made on these types of stocks.

In this article: FB, AMZN, TMO, CFR, UNH
Stocks That Have Investors (Including Me) Excited
4 years ago

Good to know, thanks!

In this article: FB, AMZN, TMO, CFR, UNH
Stocks That Have Investors (Including Me) Excited
4 years ago

Hi Joshua, any thoughts on where you think AMZN is headed? Just hit a high in intraday trading today. Thanks!

In this article: FB, AMZN, TMO, CFR, UNH
Cardiome Pharma: Why This Bio Gem Could Be An Easy Double This Year
4 years ago

Thanks very much! That helps.

In this article: CRME, MRK
Cardiome Pharma: Why This Bio Gem Could Be An Easy Double This Year
4 years ago

Fantastic article. In addition to Alexis' question, I have a few of my own. I would like to know more about your research on the license termination by Merck for the oral candidate. Any chance you could either construct another article discussing your research or elaborate here?

Also, let's say hypothetically that the FDA rejects the product. Is the company's business sustainable on alternative revenues alone?

4 years stretches far beyond the average review time for such products. Do you attribute this to a lapse in the regulatory process, or is there more to the story beyond the enrollment halt?

Thanks in advance.

In this article: CRME, MRK
EnteroMedics Spikes Up Following FDA Approval Of Neuroblocking Obesity Device
4 years ago

Also, I see the PPS consolidating in the next day or so. Very difficult to predict how post-approval stocks will act, but the trend is inherently negative. Look at Arena, Vivus, Orexigen, and Chelsea Therapeutics

In this article: ETRM, PSDV, ADMP, ATHN, ASPX, BCRX, FBRC, FWDG, RHHBY, IART, MANT, MASI, MCIG, BABY, OSUR, PZOO, SBRA, TNXP
EnteroMedics Spikes Up Following FDA Approval Of Neuroblocking Obesity Device
4 years ago

Hi Alexis, I believe the stock is down today because shareholders have realized that the extreme cost of the device ($15,000 - $30,000 per unit) could hinder sales uptake. You can read more about this on Bloomberg:

www.bloomberg.com/.../...-full-to-cost-15-000.html

In this article: ETRM, PSDV, ADMP, ATHN, ASPX, BCRX, FBRC, FWDG, RHHBY, IART, MANT, MASI, MCIG, BABY, OSUR, PZOO, SBRA, TNXP
Ligand Partner Receives Orphan Drug Designation
4 years ago

Thanks for commenting! I appreciate your insight, and I completely agree with you. I despise the fact that the said hedge fund is attempting to manipulate shareholders into believing that Ligand has no value, only to squeeze out short term gains on their massive short position. I will say, however, that Ligand is one company that always has something happening. Although there might be a vacuum of fundamental news in respect to the overall market, Ligand should benefit from a myriad of clinical updates for its respective partnerships and collaborations.

In this article: LGND
1 to 10 of 36 comments
1 2 3 4

STOCKS I FOLLOW

APHB AMPLIPHI BIOSCIENCES
ARNA Arena Pharmaceuticals, Inc.
BLFS BIOLIFE SOLUTIONS
CHK Chesapeake Energy Corporation
ECYT Endocyte Inc.
HZNP Horizon Pharma
IAG IAMGOLD Corporation
KOG Kodiak Oil & Gas Corp
OPXA Opexa Therapeutics Inc.
OXGN OXiGENE, Inc.
RNN Rexahn Pharmaceuticals Inc
RXII RXi Pharmaceuticals Corporation
SYN Synthetic Biologics
Load More

TWEETS

PERSONAL BLOG

Latest Posts

Work Experience

Legal Intern
Airbus DS Communications
May 2016 - Present (3 years 5 months)
Contributor
Seeking Alpha
March 2014 - Present (5 years 7 months)
Newsletter Provider
The Biotech Rundown
April 2014 - Present (5 years 6 months)
Freelance Writer
The Motley Fool
June 2014 - Present (5 years 4 months)
Contributor
TalkMarkets
May 2014 - Present (5 years 5 months)

Education

University of Colorado School of Law
Doctor of Law (J.D.)
2015 / 2018
Law
University of California, Davis
Bachelors in Letters and Science (Highest Honors Pending)
2011 / 2014
Political Science, Contemporary Leadership

Publications

Why AstraZeneca Could Outperform
Trevor Lowenthal
The Motley Fool
06/06/2014
BioLife Solutions: A Heavily Discounted High Growth Opportunity
Trevor Lowenthal
Seeking Alpha
05/22/2014
Rexahn Pharmaceuticals: An Undervalued Oncology Play With Risk Diversification
Trevor Lowenthal
Seeking Alpha
05/13/2014
Opexa Therapeutics: An Optimal Buyout Candidate Pending Successful Topline Results From Abili-T
Trevor Lowenthal
Seeking Alpha
04/29/2014
The Bull Case For Oragenics: Buy The 30% Discount, Hold For Long-Term Success Of The Lantibiotic Program
Trevor Lowenthal
Seeking Alpha
04/22/2014
AmpliPhi Biosciences: A Speculative Play In Biopharmaceuticals Too Compelling To Ignore
Trevor Lowenthal
Seeking Alpha
04/10/2014
OXiGENE Incorporated: An Undervalued Opportunity In Biopharmaceuticals
Trevor Lowenthal
Seeking Alpha
03/25/2014
Drain the Swamp
Trevor Lowenthal
Davis Political Review
07/01/2013